Tinnitus — B12, Magnesium and Zinc Status

Of the dozens of nutritional factors that have been investigated in tinnitus, three stand out as having both biologically plausible mechanism and reproducible association in observational and interventional studies: vitamin B12, magnesium, and zinc. Each has a defined mechanistic role in cochlear or central-auditory function, each has a documented prevalence of deficiency in tinnitus cohorts substantially higher than general population norms, and each has at least some interventional evidence of symptomatic improvement when deficiency is corrected. The combined testing of all three is inexpensive (under $100 in the US), the supplementation is safe at standard doses, and the response — while not universal — is large enough in the responder subset to justify routine assessment in every patient with chronic tinnitus.

Table of Contents

  1. Why These Three Nutrients
  2. Vitamin B12 — Mechanism and Cochlear-Nerve Demyelination
  3. Vitamin B12 — Clinical Evidence in Tinnitus
  4. Magnesium — NMDA Antagonism and Cochlear Protection
  5. Magnesium — Clinical Evidence in Tinnitus and Noise Injury
  6. Zinc — Cochlear Concentration and Hair-Cell Function
  7. Zinc — Clinical Evidence and the Cochrane Verdict
  8. Practical Testing Protocol
  9. Repletion Protocols
  10. Cautions and Interactions
  11. Key Research Papers
  12. Connections

Why These Three Nutrients

Many nutrients have been proposed for tinnitus — the literature includes case reports and small studies for vitamin D, folate, iron, manganese, selenium, coenzyme Q10, omega-3 fatty acids, and others. The reason B12, magnesium, and zinc receive the largest emphasis is the convergence of three lines of evidence specific to these three:

  1. Mechanistic role specific to the auditory system — B12 maintains myelin of the cochlear and auditory nerves; magnesium directly modulates NMDA-receptor activity at the cochlear hair-cell synapse and protects against noise-induced excitotoxicity; zinc is concentrated 100-fold in cochlear hair cells relative to plasma and plays a role in the antioxidant defense of the cochlea
  2. Documented deficiency prevalence in tinnitus cohorts — multiple case-control studies show 30–47% B12 deficiency prevalence in tinnitus patients (vs 10–15% in age-matched controls), magnesium status is consistently lower in tinnitus cohorts on RBC magnesium measurement, and zinc deficiency is documented in 25–30% of severe-tinnitus patients
  3. At least some interventional evidence of symptomatic response — B12 repletion produces improvement in approximately 40% of B12-deficient tinnitus patients per the Shemesh series; magnesium reduces noise-induced threshold shifts in military trials; zinc shows benefit in selected subgroups in the Cochrane review (though overall verdict remains equivocal)

The clinical reality is that these are inexpensive interventions with favorable safety profiles, and the cost-benefit calculation overwhelmingly favors testing and treating any documented deficiency.

Back to Table of Contents

Vitamin B12 — Mechanism and Cochlear-Nerve Demyelination

Vitamin B12 (cobalamin) is required for two enzymatic reactions in human physiology: methylmalonyl-CoA mutase (mitochondrial fatty-acid and amino-acid metabolism) and methionine synthase (the methylation cycle, regenerating methionine from homocysteine). The methionine-synthase reaction is the more relevant to nervous-system function — it produces the universal methyl-donor S-adenosylmethionine (SAMe) required for myelin basic protein synthesis and phospholipid methylation in myelin sheaths.

Severe B12 deficiency produces subacute combined degeneration of the spinal cord, peripheral neuropathy, and dementia. Less appreciated — but specifically relevant to tinnitus — is the effect on the cranial nerves, including cranial nerve VIII (the cochlear and vestibular nerve). Demyelination of the cochlear nerve disrupts conduction velocity, producing both hearing loss and the abnormal spontaneous activity that generates phantom auditory perception.

Berkiten et al. (2013) documented this objectively. B12-deficient subjects showed prolonged auditory brainstem response (ABR) waves I-III latencies and interpeak intervals compared to controls — an electrophysiologic marker of cochlear-nerve conduction slowing. The same conduction abnormality has been linked to tinnitus generation in central auditory plasticity models, providing a coherent mechanistic bridge from B12 deficiency to phantom auditory perception.

Back to Table of Contents

Vitamin B12 — Clinical Evidence in Tinnitus

The seminal clinical work was Shemesh et al. (1993) at Hadassah University Hospital in Jerusalem. The investigators measured serum B12 in 113 tinnitus patients (with and without noise-induced hearing loss) and 30 age-matched controls. Findings:

Subsequent work has confirmed the elevated B12 deficiency prevalence in tinnitus populations. Singh et al. (2016) replicated the Shemesh finding in an Indian cohort with similar deficiency rates and response to repletion. Lasisi et al. (2010) documented multi-micronutrient deficiency including B12 in tinnitus patients in Nigeria.

Important methodologic caveat: the serum B12 threshold for "deficiency" has shifted considerably over the decades. The Shemesh study used a relatively lenient cutoff (less than 250 pg/mL). Modern functional deficiency definitions use methylmalonic acid (MMA) and homocysteine as confirmatory markers — serum B12 levels in the 200–400 pg/mL range may still represent functional deficiency if MMA is elevated. The practical implication: in any tinnitus patient with serum B12 below 400 pg/mL, MMA should be measured as a confirmatory step, and repletion should be undertaken if either marker is abnormal.

Back to Table of Contents

Magnesium — NMDA Antagonism and Cochlear Protection

Magnesium is the natural physiologic antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor. The NMDA receptor channel is normally blocked by a magnesium ion at resting membrane potential; depolarization removes the magnesium block, allowing calcium influx and downstream signaling. In the cochlea, the inner hair cell-to-spiral ganglion synapse uses glutamate as the neurotransmitter, and excessive glutamate release — the mechanism behind acoustic-overexposure injury — produces excitotoxic calcium overload at the postsynaptic spiral ganglion terminal.

Magnesium status determines how effectively the NMDA receptor is protected from this excitotoxic surge. Animal models of noise-induced hearing loss consistently show that magnesium-replete subjects sustain less cochlear damage than magnesium-deficient subjects exposed to the same acoustic stimulus. The mechanism extends beyond the synapse — magnesium also maintains cochlear blood flow (it is a vasodilator), supports mitochondrial function, and reduces reactive oxygen species generation during acoustic stress.

Beyond noise protection, magnesium has a direct vascular role in cochlear blood supply. The stria vascularis is the most metabolically active tissue in the body per gram of weight, and any reduction in cochlear microcirculation acutely worsens hair-cell function. Magnesium deficiency promotes vasoconstriction (through unopposed calcium signaling in vascular smooth muscle), and several small clinical trials have shown improved cochlear blood flow on transcranial Doppler with magnesium supplementation.

Back to Table of Contents

Magnesium — Clinical Evidence in Tinnitus and Noise Injury

The Israeli Defense Forces studies by Attias and colleagues are the most rigorous interventional data for magnesium in cochlear protection. Attias et al. (1994) randomized 300 male IDF recruits during a 2-month basic-training period (which involves repeated impulse-noise exposure from rifle fire) to magnesium aspartate 167 mg/day or placebo. Results:

The Joachims 2003 replication in a young-adult civilian population reproduced the benefit at similar magnitude. Le Prell et al. (2007) demonstrated that magnesium plus vitamins A, C, and E in combination produced additive cochlear protection in animal models of noise injury, leading to the formulation of investigational "ACE-Mg" otoprotectant cocktails for impulse-noise protection.

For chronic established tinnitus (as opposed to prevention of new noise-induced injury), the evidence is thinner but suggestive. Cevette et al. (2003) reviewed the magnesium-and-hearing literature and concluded that magnesium repletion should be a standard recommendation in any tinnitus patient with documented low magnesium status. The challenge with magnesium status assessment is that serum magnesium is poorly sensitive — most magnesium is intracellular, and serum can be normal in the face of substantial cellular deficit. RBC magnesium and ionized magnesium are more sensitive but less widely available. As a practical matter, empiric magnesium repletion at 400 mg/day elemental for 90 days is reasonable in any tinnitus patient regardless of serum measurement, given the safety profile.

Back to Table of Contents

Zinc — Cochlear Concentration and Hair-Cell Function

Zinc is concentrated in the cochlea to a remarkable degree — the inner and outer hair cells contain zinc at concentrations approximately 100-fold higher than plasma. This dramatic concentration gradient suggests a specific physiologic role, and several lines of evidence point to multiple zinc-dependent functions in the auditory system:

Yetiser et al. (2002) measured serum zinc in 60 patients with severe tinnitus and 40 age-matched controls. Tinnitus patients had significantly lower serum zinc, and the zinc-deficient subgroup showed improvement on validated tinnitus questionnaires after 50 mg/day zinc supplementation for two months. The effect was modest but reproducible across multiple small trials of similar design.

Back to Table of Contents

Zinc — Clinical Evidence and the Cochrane Verdict

The Person et al. (2016) Cochrane review of zinc for tinnitus pooled three randomized controlled trials totaling 209 participants and concluded that the overall evidence does not currently support zinc supplementation as a routine intervention for unselected tinnitus patients. The verdict was cautious primarily because:

However, the Cochrane review explicitly noted that the included trials did not stratify by baseline zinc status — an important limitation. In Coelho's 2007 review and the Yetiser trial, the zinc-deficient subgroup showed clinically meaningful improvement while zinc-replete patients did not benefit. This is mechanistically expected: repleting deficiency is fundamentally different from supplementation of an already-replete individual.

The pragmatic clinical translation is therefore: zinc supplementation is justified in tinnitus patients with documented deficiency (serum zinc below approximately 70 mcg/dL or below the reference range of the testing laboratory), at doses of 25–50 mg elemental zinc per day, for 60–90 days, with reassessment of both serum zinc and tinnitus questionnaires. Empiric zinc supplementation in zinc-replete tinnitus patients is not justified by current evidence and carries small risks (copper deficiency from chronic high-dose zinc, gastric irritation).

Back to Table of Contents

Practical Testing Protocol

A reasonable nutrient-status workup at the initial tinnitus evaluation:

For US patients, this entire panel is available as a single venipuncture and typically costs under $200 even without insurance through direct-to-consumer testing platforms.

Back to Table of Contents

Repletion Protocols

When deficiency is identified, the following repletion protocols are evidence-supported and well-tolerated:

Back to Table of Contents

Cautions and Interactions

Back to Table of Contents

Key Research Papers

  1. Shemesh Z, Attias J, Ornan M, Shapira N, Shahar A (1993). Vitamin B12 deficiency in patients with chronic-tinnitus and noise-induced hearing loss. American Journal of Otolaryngology. — PubMed 8434766
  2. Singh C et al. (2016). Role of vitamin B12 in tinnitus. Indian Journal of Otolaryngology and Head & Neck Surgery. — PubMed 27340638
  3. Berkiten G et al. (2013). Influence of vitamin B12 deficiency on the auditory brainstem response. The Laryngoscope. — PubMed 23291859
  4. Attias J et al. (1994). Oral magnesium intake reduces permanent hearing loss induced by noise exposure. American Journal of Otolaryngology. — PubMed 8074840
  5. Joachims HZ et al. (2003). Oral magnesium supplementation as prophylaxis for noise-induced hearing loss in young adults. Magnesium Research. — PubMed 14600474
  6. Cevette MJ, Vormann J, Franz K (2003). Magnesium and hearing. Journal of the American Academy of Audiology. — PubMed 14655953
  7. Coelho CB, Tyler R, Hansen M (2007). Zinc as a possible treatment for tinnitus. Progress in Brain Research. — PubMed 17956802
  8. Yetiser S et al. (2002). The role of zinc in management of tinnitus. Auris Nasus Larynx. — PubMed 12393037
  9. Person OC et al. (2016). Zinc supplementation for tinnitus. Cochrane Database of Systematic Reviews. — PubMed 27858967
  10. Lasisi AO et al. (2010). Plasma levels of micronutrients in tinnitus patients in a developing country. Ear Nose Throat J. — PubMed 20649146
  11. Le Prell CG et al. (2007). Free radical scavengers vitamins A, C, and E plus magnesium reduce noise trauma. Free Radical Biology & Medicine. — PubMed 17449231
  12. Ocak E et al. (2018). Decreased serum magnesium and zinc in patients with idiopathic sudden sensorineural hearing loss. Indian J Otolaryngol. — PubMed 29977806

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents